EBR Systems Says Number of Heart Pacing System Implants Doubled in Q4 2025; Shares Rise 7%

MT Newswires Live

01/12

EBR Systems (ASX:EBR) said that its WiSE heart pacing system was implanted in 18 commercial patients during the fourth quarter of 2025, doubling the number of implants from the third quarter, according to a Monday Australian bourse filing.

An additional nine purchase agreements were signed with target centers during the December 2025 quarter, the filing said.

During the period, four patients were enrolled in the WiSE system utilization and performance study, a prospective observational study designed to evaluate real-world outcomes for heart failure patients receiving the WiSE system using left ventricular endocardial pacing for cardiac resycnhronization therapy.

The study will follow more than 300 commercial patients across 50 centers over a five-year period.

Looking ahead, the company expects to report revenue of $870,000 to $935,000 for the fourth quarter and $1.5 million to $1.6 million for 2025.

EBR Systems' shares rose 7% in recent trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602560462"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602560462\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602560462?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 12:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602560462","market":"us","top_or_hot":-1,"title":"EBR Systems Says Number of Heart Pacing System Implants Doubled in Q4 2025; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> EBR Systems (ASX:EBR) said that its WiSE heart pacing system was implanted in 18 commercial patients during the fourth quarter of 2025, doubling the number of implants from the third quarter, according to a Monday Australian bourse filing.</p><p>An additional nine purchase agreements were signed with target centers during the December 2025 quarter, the filing said.</p><p>During the period, four patients were enrolled in the WiSE system utilization and performance study, a prospective observational study designed to evaluate real-world outcomes for heart failure patients receiving the WiSE system using left ventricular endocardial pacing for cardiac resycnhronization therapy.</p><p>The study will follow more than 300 commercial patients across 50 centers over a five-year period.</p><p>Looking ahead, the company expects to report revenue of $870,000 to $935,000 for the fourth quarter and $1.5 million to $1.6 million for 2025.</p><p>EBR Systems' shares rose 7% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EBR Systems Says Number of Heart Pacing System Implants Doubled in Q4 2025; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEBR Systems Says Number of Heart Pacing System Implants Doubled in Q4 2025; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-12 12:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> EBR Systems (ASX:EBR) said that its WiSE heart pacing system was implanted in 18 commercial patients during the fourth quarter of 2025, doubling the number of implants from the third quarter, according to a Monday Australian bourse filing.</p><p>An additional nine purchase agreements were signed with target centers during the December 2025 quarter, the filing said.</p><p>During the period, four patients were enrolled in the WiSE system utilization and performance study, a prospective observational study designed to evaluate real-world outcomes for heart failure patients receiving the WiSE system using left ventricular endocardial pacing for cardiac resycnhronization therapy.</p><p>The study will follow more than 300 commercial patients across 50 centers over a five-year period.</p><p>Looking ahead, the company expects to report revenue of $870,000 to $935,000 for the fourth quarter and $1.5 million to $1.6 million for 2025.</p><p>EBR Systems' shares rose 7% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBR.AU","symbol_name":"EBR SYSTEMS INC-CDI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2602560462","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602560462","pubTimestamp":1768191579,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"EBR Systems  said that its WiSE heart pacing system was implanted in 18 commercial patients during the fourth quarter of 2025, doubling the number of implants from the third quarter, according to a Monday Australian bourse filing.An additional nine purchase agreements were signed with target centers during the December 2025 quarter, the filing said.During the period, four patients were enrolled in the WiSE system utilization and performance study, a prospective observational study designed to evaluate real-world outcomes for heart failure patients receiving the WiSE system using left ventricular endocardial pacing for cardiac resycnhronization therapy.The study will follow more than 300 commercial patients across 50 centers over a five-year period.Looking ahead, the company expects to report revenue of $870,000 to $935,000 for the fourth quarter and $1.5 million to $1.6 million for 2025.EBR Systems' shares rose 7% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EBR.AU":"EBR SYSTEMS INC-CDI","BK7007":"医疗保健设备"},"translate_title":"EBR Systems表示，2025年第四季度心脏起搏系统植入数量翻了一番；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBR.AU":1},"content_text":"EBR Systems (ASX:EBR) said that its WiSE heart pacing system was implanted in 18 commercial patients during the fourth quarter of 2025, doubling the number of implants from the third quarter, according to a Monday Australian bourse filing.An additional nine purchase agreements were signed with target centers during the December 2025 quarter, the filing said.During the period, four patients were enrolled in the WiSE system utilization and performance study, a prospective observational study designed to evaluate real-world outcomes for heart failure patients receiving the WiSE system using left ventricular endocardial pacing for cardiac resycnhronization therapy.The study will follow more than 300 commercial patients across 50 centers over a five-year period.Looking ahead, the company expects to report revenue of $870,000 to $935,000 for the fourth quarter and $1.5 million to $1.6 million for 2025.EBR Systems' shares rose 7% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}